PROTEIN KINASE C IOTA
The invention involves PKCι signaling. The invention provides, for example, transgenic animals, inhibitors of PKCι signaling, methods for inhibiting PKCι signaling, methods for identifying inhibitors of PKCι signaling, and methods for diagnosing cancer.
This application is a divisional of U.S. application Ser. No. 10/592,289, filed Jul. 23, 2007, which is a National Stage application under 35 U.S.C. §371 and claims benefit under 35 U.S.C. §119(a) of International Application No. PCT/US2005/007935 having an International Filing Date of Mar. 8, 2005, which claims the benefit of U.S. Provisional Application Ser. No. 60/551,288, filed Mar. 8, 2004.
STATEMENT AS TO FEDERALLY SPONSORED RESEARCHThis invention was made with government support under 5R01CA081436-09 and 5R01CA094122-06 awarded by The National Institutes of Health National Cancer Institute. The government has certain rights in the invention.
BACKGROUND1. Technical Field
The invention relates to methods and materials involved in protein kinase C iota signaling. The invention also relates to transgenic animals, inhibitors of protein kinase C iota signaling, methods for inhibiting protein kinase C iota signaling, methods for identifying inhibitors of protein kinase C iota signaling, and methods for diagnosing cancer.
2. Background Information
Protein kinase C iota (PKC iota or PKCι) plays a requisite role in Bcr-Abl mediated resistance to chemotherapy-induced apoptosis (Jamieson et al., J. Biol. Chem., 274:3927-3930 (1999) and Murray et al., J. Biol. Chem., 272:27521-4 (1997)), and is critical for epithelial cell polarity (Suzuki et al., J. Cell Sci., 115:3565-73 (2002)) and cell survival (Jamieson et al., J. Biol. Chem., 274:3927-3930 (1999) and Murray et al., J. Biol. Chem., 272:27521-4 (1997)). PKCι has also been implicated in Ras-mediated signaling (Coghlan et al., Mol. Cell. Biol., 20:2880-9 (2000); Kampfer et al, J. Biol. Chem., 276:42834-42 (2001); and Uberall et al 1., J. Cell Biol., 144:413-25 (1999)). Activating Ras mutations occur in about 30 percent of all human cancers (Adjei, J. Natl. Cancer Inst., 93:1062-74 (2001)), and in about 50 percent of human colon adenomas and carcinomas (Bos, Cancer Res., 49:4682-9 (1989)). Ras mutations are an early event in colon carcinogenesis and are often present in preneoplastic lesions in the colon (Pretlow et al., J. Natl. Cancer Inst., 85:2004-7 (1993) and Zaidi et al, Carcinogenesis., 16:451-6 (1995)).
SUMMARYThe invention involves PKCι signaling. The invention relates to transgenic animals, inhibitors of PKCι signaling, methods for inhibiting PKCι signaling, methods for identifying inhibitors of PKCι signaling, and methods for diagnosing cancer. As described herein, Ras-mediated transformation, invasion, and anchorage-independent growth of cells (e.g., intestinal epithelial cells) requires PKCι activity. In addition, PKCι is involved in Ras- and carcinogen-mediated colon carcinogenesis in vivo. PKCι also is involved in other cancers including, without limitation, lung cancers. For example, transgenic mice expressing constitutively active PKCι (caPKCι) in the colon are highly susceptible to carcinogen-induced colon carcinogenesis, whereas mice expressing kinase-deficient PKCι (kdPKCι) are resistant to both carcinogen- and oncogenic Ras-mediated carcinogenesis. Expression of kdPKCι in Ras-transformed rat intestinal epithelial (RIE/Ras) cells blocks oncogenic Ras-mediated activation of Rac1, cellular invasion, and anchorage-independent growth. Constitutively active Rac1 (RacV12) restores invasiveness and anchorage-independent growth in RIE/Ras cells expressing kdPKCι. These results demonstrate that PKCι is required for oncogenic Ras- and carcinogen-mediated carcinogenesis (e.g., colon carcinogenesis) in vivo and define a pro-carcinogenic signaling axis consisting of Ras, PKCι, and Rac1.
In general, the invention features a transgenic rodent, the nucleated cells of which contain a transgene, the transgene containing a promoter sequence operably linked to a nucleic acid sequence encoding a protein kinase C iota polypeptide, wherein the transgenic rodent expresses the protein kinase C iota polypeptide and develops more preneoplastic colonic lesions after azoxymethane treatment than a corresponding wild-type rodent treated with the azoxymethane. The transgenic rodent can be a mouse. The protein kinase C iota polypeptide can be a constitutively active protein kinase C iota polypeptide. The promoter sequence can promote expression in a cell from the colonic epithelium. The promoter sequence can contain a sequence present in a liver fatty acid-binding protein gene. The promoter sequence can be an Fabp14x at −132 promoter sequence.
In another embodiment, the invention features a transgenic rodent, the nucleated cells of which contain a transgene, the transgene containing a promoter sequence operably linked to a nucleic acid sequence encoding a protein kinase C iota polypeptide lacking protein kinase C iota activity, wherein the transgenic rodent expresses the protein kinase C iota polypeptide and exhibits less protein kinase C iota activity in the colonic epithelium than a corresponding wild-type rodent. The transgenic rodent can be a mouse. The promoter sequence can promote expression in a cell from the colonic epithelium. The promoter sequence can contain a sequence present in a liver fatty acid-binding protein gene. The promoter sequence can be a Fabp14x at −132 promoter sequence. The nucleated cells can contain a second transgene, the second transgene containing a second promoter sequence operably linked to a second nucleic acid sequence encoding a ras polypeptide. The ras polypeptide can be a K-Ras polypeptide. The transgenic rodent can develop fewer aberrant crypt foci in the proximal colon than a corresponding rodent with nucleated cells containing the second transgene and lacking the transgene. The transgenic rodent can be a K-RasLA2/kdPKCι mouse.
In another aspect, the invention features progeny of a transgenic rodent, wherein the nucleated cells of the transgenic rodent contain a transgene, the transgene containing (a) a promoter sequence operably linked to a nucleic acid sequence encoding a protein kinase C iota polypeptide, wherein the transgenic rodent expresses the protein kinase C iota polypeptide and develops more preneoplastic colonic lesions after azoxymethane treatment than a corresponding wild-type rodent treated with the azoxymethane, or (b) a promoter sequence operably linked to a nucleic acid sequence encoding a protein kinase C iota polypeptide lacking protein kinase C iota activity, wherein the transgenic rodent expresses the protein kinase C iota polypeptide and exhibits less protein kinase C iota activity in the colonic epithelium than a corresponding wild-type rodent. The nucleated cells of the progeny contain the transgene.
In another aspect, the invention features an isolated cell of a transgenic rodent wherein the nucleated cells of the transgenic rodent contain a transgene, the transgene containing (a) a promoter sequence operably linked to a nucleic acid sequence encoding a protein kinase C iota polypeptide, wherein the transgenic rodent expresses the protein kinase C iota polypeptide and develops more preneoplastic colonic lesions after azoxymethane treatment than a corresponding wild-type rodent treated with the azoxymethane, or (b) a promoter sequence operably linked to a nucleic acid sequence encoding a protein kinase C iota polypeptide lacking protein kinase C iota activity, wherein the transgenic rodent expresses the protein kinase C iota polypeptide and exhibits less protein kinase C iota activity in the colonic epithelium than a corresponding wild-type rodent.
In another aspect, the invention features a method for inhibiting a protein kinase C iota polypeptide response in a mammal. The method includes administering an inhibitor to the mammal under conditions wherein the response is inhibited, wherein the inhibitor reduces the interaction between a protein kinase C iota polypeptide and a polypeptide selected from the group consisting of Par-6, Src, Par-4, p62/ZIP, and Par-3 polypeptides. The response can be cell transformation, development of cancer, and/or colon carcinogenesis. The inhibitor can be a polypeptide fragment. The polypeptide fragment can contain an amino acid sequence present in the protein kinase C iota polypeptide. The inhibitor can be aurothioglucose, aurothiomaleate, thimerosal, phenylmercuric acetate, ebselen, cisplatin, apomorphine, pyrantel pamoate, gossypol-acetic acid complex, ellagic acid, or hexestrol.
In another aspect, the invention features a method for identifying an agent that inhibits transformation of a cell. The method includes (a) administering a test agent and a carcinogen to a transgenic rodent, the nucleated cells of which contain a transgene containing a promoter sequence operably linked to a nucleic acid sequence encoding a protein kinase C iota polypeptide, wherein the transgenic rodent expresses the protein kinase C iota polypeptide and develops more preneoplastic colonic lesions after azoxymethane treatment than a corresponding wild-type rodent treated with the azoxymethane, and (b) determining if the test agent inhibits cell transformation in the transgenic rodent as compared with a corresponding transgenic rodent to which the test agent has not been administered. The cell can be an intestinal cell. The test agent can be a test polypeptide. The test polypeptide can contain an amino acid sequence present in a protein kinase C iota polypeptide. The protein kinase C iota polypeptide can be a constitutively active protein kinase C iota polypeptide. The carcinogen can be azoxymethane or dimethylhydrazine.
In another aspect, the invention features a method for identifying an agent that inhibits the interaction between a protein kinase C iota polypeptide and a polypeptide selected from the group consisting of Par-6, Src, Par-4, p62/ZIP, and Par-3 polypeptides. The method includes (a) contacting a test agent with the protein kinase C iota polypeptide and the polypeptide, wherein the protein kinase C iota polypeptide and the polypeptide each contain a fluorescent molecule under conditions wherein fluorescent resonance energy transfer is detectable when the protein kinase C iota polypeptide interacts with the polypeptide, and (b) determining whether or not the presence of the test agent reduced fluorescent resonance energy transfer between the protein kinase C iota polypeptide and the polypeptide as compared to the fluorescent resonance energy transfer observed between the protein kinase C iota polypeptide and the polypeptide in the absence of the test agent, wherein a reduction is the fluorescent resonance energy transfer observed between the protein kinase C iota polypeptide and the polypeptide in the presence of the test agent indicates that the test agent is the agent. The polypeptide can be a Par-6 polypeptide. The test agent can be a test polypeptide. The test polypeptide can contain an amino acid sequence present in a protein kinase C iota polypeptide. The test agent can be aurothioglucose, aurothiomaleate, thimerosal, phenylmercuric acetate, ebselen, cisplatin, apomorphine, pyrantel pamoate, gossypol-acetic acid complex, ellagic acid, or hexestrol.
In another aspect, the invention features a method for determining whether or not a mammal is developing cancerous cells. The method includes determining whether or not the mammal contains an elevated level of a protein kinase C iota polypeptide, wherein the presence of the elevated level of the protein kinase C iota polypeptide indicates that the mammal is developing cancerous cells. The cells can be intestinal cells. The mammal can be a human.
In another aspect, the invention features a transgenic rodent, the nucleated cells of which contain a transgene. The transgene contains a promoter sequence operably linked to a nucleic acid sequence encoding a protein kinase C iota polypeptide, where the transgenic rodent is capable of expressing the protein kinase C iota polypeptide in lung tissue. The a promoter sequence can be an inducible promoter sequence. The protein kinase C iota polypeptide can be a kinase-deficient protein kinase C iota polypeptide. The carcinogen can be N-nitroso-tris-chloroethylurea. The transgenic rodent can develop more cancerous lesions after carcinogen treatment or expression of a ras polypeptide than a comparable rodent lacking said transgene.
In another aspect, the invention features a method for inhibiting the binding of a protein kinase C iota polypeptide to a Par-6 polypeptide. The method includes contacting the protein kinase C iota polypeptide or the Par-6 polypeptide with a protein kinase C iota polypeptide/Par-6 polypeptide inhibitor. The protein kinase C iota polypeptide/Par-6 polypeptide inhibitor can be aurothioglucose, aurothiomaleate, thimerosal, phenylmercuric acetate, ebselen, cisplatin, apomorphine, pyrantel pamoate, gossypol-acetic acid complex, ellagic acid, or hexestrol.
In another aspect, the invention features a method for assessing the prognosis of a mammal (e.g., human) having lung cancer. The method includes determining whether or not the mammal contains cancer cells having an increased copy number of nucleic acid encoding a protein kinase C iota polypeptide or an increased level of protein kinase C iota polypeptide expression or activity, as compared to the copy number or level observed in control cells (e.g., non-cancerous control cells).
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
The invention provides methods and materials related to PKCι signaling. It is noted that PKCι generally refers to a human polypeptide. The corresponding polypeptide in rodents, which is about 95 percent homologous at the amino acid level to human PKCι, is generally referred to as protein kinase C lambda. For the purpose of this document, the term “PKCι” refers to any PKCι polypeptide including, without limitation, human PKCι polypeptides and rodent protein kinase C lambda.
In some embodiments, the invention provides transgenic non-human animals. Such non-human animals can be farm animals such as pigs, goats, sheep, cows, horses, and rabbits, rodents such as rats, guinea pigs, and mice, and non-human primates such as baboons, monkeys, and chimpanzees. The term “transgenic non-human animal” as used herein includes, without limitation, founder transgenic non-human animals as well as progeny of the founders, progeny of the progeny, and so forth, provided that the progeny retain the transgene. The nucleated cells of the transgenic non-human animals provided herein can contain a transgene that includes a promoter sequence operably linked to a nucleic acid sequence encoding a PKCι polypeptide. A PKCι polypeptide can be a wild-type PKCι polypeptide (e.g., wild-type human PKCι), a constitutively active PKCι polypeptide (e.g., constitutively active human PKCι), or a kinase deficient PKCι polypeptide (e.g., kinase deficient human PKCι). The transgenic non-human animal can express the PKCι polypeptide and can develop more preneoplastic colonic lesions after carcinogen (e.g., azoxymethane) treatment than a corresponding wild-type non-human animal treated with the carcinogen.
The nucleic acid sequence encoding the PKCι polypeptide can be a cDNA or can include introns or adjacent 5′- or 3′-untranslated regions (e.g., a genomic nucleic acid). The nucleic acid sequence encoding the PKCι polypeptide can be operably linked to any promoter sequence. For example, a promoter sequence that facilitates the expression of a nucleic acid without significant tissue- or temporal-specificity can be used. Examples of such promoter sequences include, without limitation, viral promoters such as a herpes virus thymidine kinase (TK) promoter sequence, a SV40 promoter sequence, or a cytomegalovirus (CMV) promoter sequence. In some examples, nucleic acid encoding a PKCι polypeptide can be operably linked to a tissue-specific promoter sequence such as a colon-specific promoter sequence (e.g., a Fabp14x at −132 promoter sequence). Other tissue-specific promoter sequences include, without limitation, those listed in Table 1.
In some cases, an inducible promoter sequence can be used. For example, a Tet-on or Tet-off expression system can be used to design one or more constructs that allow expression to be regulated in response to a drug (e.g., tetracycline or doxycycline). Briefly, Tet-on and Tet-off expression systems are binary transgenic systems in which expression from a target transgene depends on the activity of an inducible transcriptional activator. In both the Tet-on and Tet-off systems, expression of the transcriptional activator can be regulated both reversibly and quantitatively by exposing a transgenic animal to varying concentrations of tetracycline or a tetracycline derivatives such as doxycycline. In some cases, a Tet-on or Tet-off system can be used with a tissue-specific promoter sequence (e.g., a lung-specific promoter sequence) such that a PKCι polypeptide is expressed in a particular tissue (e.g., lung tissue) in response to changes in, for example, tetracycline or doxycycline.
The term “operably linked” as used herein refers to positioning a regulatory element (e.g., a promoter sequence, an inducible element, or an enhancer sequence) relative to a nucleic acid sequence encoding a polypeptide in such a way as to permit or facilitate expression of the encoded polypeptide. In the transgenes disclosed herein, for example, an enhancer can be positioned 3′ or 5′ relative to the nucleic acid encoding a PKCι polypeptide, and can be positioned within the transgene in either the 5′ to 3′ or the 3′ to 5′ orientation.
Various techniques known in the art can be used to introduce transgenes into non-human animals to produce founder lines, in which the transgene is integrated into the genome. Such techniques include, without limitation, pronuclear microinjection (See, e.g., U.S. Pat. No. 4,873,191), retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci. USA, 82:6148-1652 (1985)), gene targeting into embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)), electroporation of embryos (Lo, Mol. Cell. Biol., 3:1803-1814 (1983)), and in vitro transformation of somatic cells, such as cumulus or mammary cells, followed by nuclear transplantation (Wilmut et al., Nature, 385:810-813 (1997); and Wakayama et al., Nature, 394:369-374 (1998)). For example, fetal fibroblasts can be genetically modified to express a PKCι polypeptide, and then fused with enucleated oocytes. After activation of the oocytes, the eggs are cultured to the blastocyst stage. See, for example, Cibelli et al., Science, 280:1256-1258 (1998). Standard breeding techniques can be used to create animals that are homozygous for the transgene from the initial heterozygous founder animals. Homozygosity is not required, however, as the phenotype can be observed in hemizygotic animals.
Once transgenic non-human animals have been generated, expression of a PKCι polypeptide can be assessed using standard techniques. Initial screening can be accomplished by Southern blot analysis to determine whether or not integration of the transgene has taken place. For a description of Southern analysis, see sections 9.37-9.52 of Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, second edition, Cold Spring Harbor Press, Plainview; NY. Polymerase chain reaction (PCR) techniques also can be used in the initial screening. PCR refers to a procedure or technique in which target nucleic acids are amplified. Generally, sequence information from the ends of the region of interest or beyond is employed to design oligonucleotide primers that are identical or similar in sequence to opposite strands of the template to be amplified. PCR can be used to amplify specific sequences from DNA as well as RNA, including sequences from total genomic DNA or total cellular RNA. Primers typically are 14 to 40 nucleotides in length, but can range from 10 nucleotides to hundreds of nucleotides in length. PCR is described in, for example PCR Primer: A Laboratory Manual, ed. Dieffenbach and Dveksler, Cold Spring Harbor Laboratory Press, 1995. Nucleic acids also can be amplified by ligase chain reaction, strand displacement amplification, self-sustained sequence replication, or nucleic acid sequence-based amplified. See, for example, Lewis, Genetic Engineering News, 12:1 (1992); Guatelli et al., Proc. Natl. Acad. Sci. USA, 87:1874-1878 (1990); and Weiss, Science, 254:1292-1293 (1991).
Expression of a nucleic acid sequence encoding a PKCι polypeptide in the tissues of transgenic non-human animals can be assessed using techniques that include, without limitation, Northern blot analysis of tissue samples obtained from the animal (e.g., intestinal tissue), in situ hybridization analysis, Western analysis, immunoassays such as enzyme-linked immunosorbent assays, and reverse-transcriptase PCR(RT-PCR). As described herein, expression of a constitutively active PKCι polypeptide can result in transgenic animals exhibiting more preneoplastic colonic lesions after carcinogen (e.g., azoxymethane) treatment than a corresponding wild-type animal treated with the carcinogen.
In some embodiments, transgenic animals containing a transgene that encodes a PKCι polypeptide lacking protein kinase C iota activity can exhibit less protein kinase C iota activity in, for example, the colonic epithelium than a corresponding wild-type rodent. It is understood that a particular phenotype in a transgenic animal typically is assessed by comparing the phenotype in the transgenic animal to the corresponding phenotype exhibited by a control non-human animal that lacks the transgene.
In some embodiments, the transgenic non-human animals can include a second transgene that contains a nucleic acid sequence of an oncogene such as ras (e.g., a K-Ras polypeptide). The nucleic acid sequence of human K-ras can be obtained from GenBank (e.g., GenBank Accession No. NM—033360). The second transgene also can include regulatory elements as discussed above (e.g., a tissue-specific promoter sequence).
The invention also provides tissues (e.g., colon sections, lung sections, etc.) and cells (e.g., intestinal cells, lung cells, etc.) obtained from the transgenic non-human animals provided herein.
In addition, the invention provides inhibitors of PKCι signaling. For example, a polypeptide sequence corresponding to amino acids 1-113 of a PKCι polypeptide can be used to block Ras-mediated transformation. Expression of the 1-113 polypeptide region of PKCι appears to block PKCι signaling through disruption of protein/protein interactions between PKCι and Par-6. Polypeptides shorter (e.g., the 1-110 region, the 5-113 region, the 10-113 region, or 5-110 region) or longer (e.g., the 1-115 region, the 1-117 region, or the 1-120 region) than a 113 amino acid fragment of a PKCι polypeptide can be used as an inhibitor of PKCι signaling.
In addition, polypeptides derived from other regions of PKCι that are involved in the interaction of PKCι with other signaling molecules (e.g., Src, Par-4, p62/ZIP, and Par-3 polypeptides) can be used as inhibitors of PKCι signaling. Likewise, the corresponding regions on molecules such as Par-6, Src, Par-4, p62/ZIP, and Par-3 that mediate the binding of these molecules to PKCι can be used as inhibitors. Regions that can be used to design an inhibitor include, without limitation, (a) the MOO domain that mediates binding of Src to PKCι and (b) sites on PKCι that are phosphorylated (either by PKCι itself or by other kinases). For example, Src phosphorylates multiple sites on PKCι including tyrosines 256, 271 and 325 (Wooten et al., Mol. Cell. Biol., 21:8414-8427 (2001)). Phosphorylation at Y325 can be responsible for src-mediated activation of PKCι activity. Polypeptides surrounding this region can act as inhibitors of src-mediated activation of PKCι. Likewise, phosphorylation of Y256 (by src or other kinases) can regulate the ability of PKCι to enter the nucleus of the cell (White et al., J. Cell. Biochem., 85:42-53 (2002)), although other regions on PKCι can also be involved in regulating nuclear localization of PKCι (Perander et al., J. Biol. Chem., 276:13015-13024 (2001)). Expression of polypeptides surrounding any of these regions of PKCι can be used to disrupt PKCι signaling.
In some embodiments, an inhibitor of PKCι signaling is not a polypeptide. Examples of non-polypeptide inhibitors of PKCι signaling include, without limitation, aurothioglucose, aurothiomaleate, thimerosal, phenylmercuric acetate, ebselen, cisplatin, apomorphine, pyrantel pamoate, gossypol-acetic acid complex, ellagic acid, and hexestrol.
The invention also provides methods for identifying PKCι signaling inhibitors. In general, such methods include (a) designing an assay to measure the binding of a PKCι polypeptide and a polypeptide (e.g., a Par6 polypeptide) that interacts with a PKCι polypeptide and (b) screening for compounds that disrupt this interaction. For example, expression plasmids can be designed to express a fragment of a Par6 polypeptide (e.g. amino acids 1-125 of a human Par6 polypeptide) as a fusion protein containing a naturally fluorescent protein (e.g., cyan fluorescent protein (CFP) or yellow fluorescent protein (YFP)). Another set of plasmids can be designed to express a region of a PKCι polypeptide (e.g., amino acids 1-113 or a full-length PKCι polypeptide) that binds to the Par6 region. This region of a PKCι polypeptide also can be expressed as a fusion protein with either CFP or YFP. The binding of these recombinant polypeptides can be followed by measuring fluorescence from the polypeptides when the complex is excited by a specific wave length of light. CFP and YFP fluoresce when they are stimulated by light. However, the wavelength of light that excites CFP is different from that which excites YFP. Thus, if one wavelength of light is used, CFP can emit cyan fluorescent light but YFP will not fluoresce. If a different wavelength of light is used, YFP can fluoresce yellow, but CFP will not fluoresce. When CFP and YFP are brought into very close proximity, such as when Par6/CFP and PKCι/YFP bind to each other, and when the wavelength of light is used that will cause CFP to emit cyan fluorescent light, then some of the energy that would ordinarily be emitted as cyan colored light will be transferred to the adjacent YFP molecule on the PKCι/YFP molecule. This energy can excite YFP to emit yellow fluorescent light. This process of energy transfer from CFP to YFP is called fluorescence energy transfer (FRET). FRET can be a very sensitive way of measuring binding between two molecules that contain CFP and YFP. For example, when Par6/CFP and PKCl/YFP (or the converse pair: Par6/YFP and PKCι/CFP) are put together, FRET can occur. In addition, FRET can be used to assess binding of these two molecules since when binding is disrupted, FRET can be abolished.
In one embodiment, recombinant Par6/CFP and PKCι/YFP polypeptides can be added to the wells of either 96 well or 384 well plates. Then, a single compound from a large compound library can be added to each of the individual wells. The entire plate can be placed in a fluorescence plate reader that can measure FRET in each of the wells. Those wells that show a decrease or loss of FRET can contain a compound that can potentially disrupt the interaction between Par6 and PKCι. Appropriate controls can be included in the assay to avoid identifying compounds that inhibit FRET by other, non-specific means. This type of assay can be adapted for high throughput screening of compound libraries containing thousands and even hundreds of thousands of compounds.
Once a compound is identified as being a candidate for disrupting the interaction of Par6 and PKCι polypeptides, the compound can be put through a secondary screen in which its ability to disrupt Par6/PKCι polypeptide binding is determined in cells expressing recombinant Par6 and PKCι polypeptides. Compounds that disrupt Par6/PKCι polypeptide binding in cells can be further screened for the ability to inhibit PKCι-dependent cellular transformation.
The invention also provides methods for diagnosing cancer. For example, samples can be obtained and assessed for the presence of an elevated level of PKCι polypeptides or an elevated level of PKCι polypeptide activity. The presence of an elevated level of PKCι polypeptides or elevated level of PKCι polypeptide activity can indicate the presence of cancer and/or precancerous cells. Any method can be used to assess the level of PKCι polypeptide expression. For example, immunoblot analysis and/or immunohistochemistry can be used to examine the expression of PKCι polypeptides in tissue and/or cell samples. In some cases, PKCι polypeptide activity can be assessed using any of the methods provided herein.
The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
EXAMPLES Example 1 Methods and Materials Analysis of PKCι Expression in Mouse and Human Colon TumorsAOM-induced colon tumors were produced in C57B1/6 mice as described elsewhere (Gokmen-Polar et al., Cancer Res., 61:1375-81 (2001)). Fresh frozen tissue from human colon carcinomas and uninvolved colonic epithelium was obtained from surgical specimens. Isolation of RNA and protein for RT-PCR and immunoblot analysis, respectively, was performed as described elsewhere (Gokmen-Polar et al., Cancer Res., 61:1375-81 (2001)). Immunoblot analysis for PKCι and actin was conducted using isozyme-specific antibody against PKCι and actin (Santa Cruz, Inc.) as described elsewhere (Gokmen-Polar et al., Cancer Res., 61:1375-81 (2001) and Murray et al., J. Biol. Chem., 272:27521-4 (1997)). This PKCι antibody recognizes PKCι, but not PKCζ(Murray et al., J. Biol. Chem., 272:27521-4 (1997)).
Primers for RT-PCR analysis were as follows: PKCι forward primer: 5′-GCTTA-TGTTTGAGATGATGGCGG-3′ (SEQ ID NO:5), PKCι reverse primer: 5-GTGACA-ACCCAATCGTTCCG-3′ (SEQ ID NO:6); actin forward primer: 5′-GTGGGC-CGCTCTAGGCACCAA-3′ (SEQ ID NO:7), actin reverse primer: 5′-CTCTTTGAT-GTCACGCACGATTTC-3′ (SEQ ID NO:8).
Colon tumors and uninvolved colonic epithelium from AOM-treated mice were fixed in 10% buffered formalin, sectioned, and subjected to antigen retrieval (Vector Labs). Immunohistochemical detection of PKCι was performed using the specific PKCι antibody (Santa Cruz) and the DAKO LSAB2 (DAB) detection system (DAKO). Specificity of immunostaining for PKCι was demonstrated by inclusion of a 5-fold molar excess of the peptide used to generate the PKCι antibody (Santa Cruz) in the antibody dilution. Digital images were acquired on an Olympus DX51 microscope equipped with a DP70 digital camera using a 20× objective lens. Images were captured using the DP Controller software and processed in Adobe Photoshop.
Production of Transgenic Mice and Carcinogenesis StudiesNucleic acid encoding a constitutively active human PKCι (caPKCι) and nucleic acid encoding a kinase deficient human PKCι (kdPKCι) were generated and characterized elsewhere (Jamieson et al., J. Biol. Chem., 274:3927-3930 (1999) and Lu et al., Oncogene, 20:4777-4792 (2001)). Transgenic caPKCι and kdPKCι mice were generated on a C57B1/6 background using the Fabp14x at −132 promoter (Simon et al., J. Biol. Chem., 272:10652-63 (1997); provided by J. Gordon, Washington University, St. Louis, Mo.) to direct transgene expression to the colonic epithelium (Murray et al., J. Cell Biol., 145:699-711 (1999)). Isolation of colonic epithelium, immunoblot analysis for PKCι, and immunoprecipitation histone kinase assays were described elsewhere (Jamieson et al., J. Biol. Chem., 274:3927-3930 (1999) and Murray et al., J. Cell Biol., 145:699-711 (1999)). Transgenic caPKCι, transgenic kdPKCι, and non-transgenic mice were injected with either AOM (10 mg/kg) or saline as described elsewhere (Gokmen-Polar et al., Cancer Res., 61:1375-81 (2001)). ACF analysis was performed 12 weeks after the last AOM injection (Murray et al., J. Cell Biol., 157:915-920 (2002)), using well-defined criteria (McLellan et al., Carcinogenesis, 12:2093-8 (1991). Mice were analyzed at 40 weeks for tumor number, size, location, and pathological grade as described elsewhere (Gokmen-Polar et al., Cancer Res., 61:1375-81 (2001)). All tumors were classified as either tubular adenomas or intramucosal carcinomas (carcinoma in situ) by a board-certified pathologist. Digital images of the tumors were captured using a Nikon Eclipse E600 microscope equipped with a ProgRes C14 camera (Jenoptik, Jena, Germany) using a 20× objective lens. Images were acquired using ProgRes C14 software with Microsoft Photoeditor and processed with Microsoft Photoshop.
Transgenic K-rasLA2 mice (Johnson et al., Nature, 410:1111-6 (2001); provided by T. Jacks, M.I.T., Boston, Mass.) were bred to transgenic kdPKCι mice to obtain bi-transgenic K-rasLA2/kdPKCι mice. At 12 weeks of age, transgenic K-rasLA2 and transgenic K-rasLA2/kdPKCι mice were assessed for spontaneous ACF formation (McLellan et al., Carcinogenesis, 12:2093-8 (1991) and Murray et al., J. Cell Biol., 145:699-711 (1999)).
RIE Cell Transfections and Cellular AnalysesRIE cells and derivatives were grown in DMEM containing 5% FBS as described elsewhere (Ko et al., Oncogene, 16:3445-54 (1998)). RIE/Ras cells were described elsewhere (Sheng et al., J. Biol. Chem., 275:6628-35 (2000); provided by Dr. H. M. Sheng, University of Texas Medical Branch, Galveston, Tex.). Microarray analysis of RIE/Ras cells demonstrated that these cells express no PKCζ. cDNAs encoding human wtPKCι and kdPKCι were cloned into the pBABE/FLAG/puro retroviral expression vector, and virus stocks were produced using Phoenix-E cells (provided by Dr. G. Nolan, Stanford University, Palo Alto, Calif.). Puromycin-resistant, stable transfectants were generated. Expression of FLAG-epitope-tagged PKCι was confirmed by immunoblot analysis using an anti-FLAG antibody (Sigma-Aldrich), and PKCι kinase activity was determined by immunoprecipitation histone kinase assay as described elsewhere (Jamieson et al., J. Biol. Chem., 274:3927-3930 (1999)).
Recombinant retroviruses containing a dominant negative Rac1 (RacN17) that is Myc-tagged or a Myc-tagged RacV12 were generated by excising the Myc-tagged Rac1 constructs from pEXV/Rac vectors (Qiu et al., Nature, 374:457-9 (1995)) with EcoRI and ligating them into the EcoRI site of the LZRS-GFP retrovirus. The entire coding sequence of each construct was confirmed by DNA sequence analysis. LZRS-GFP-Rac1 retroviruses were used to infect RIE cells and derivative cell lines as described elsewhere (Ireton et al., J. Cell Biol., 159:465-76 (2002)). Rac1 activity was assessed by affinity-isolation of GTP-bound Rac1 as described elsewhere (Sander et al., J. Cell Biol., 143:1385-98 (1998)). Active GTP-bound Rac1 and total Rac1 were identified by immunoblot analysis using a Rac1 monoclonal antibody (BD Transduction Laboratories) and quantitated by densitometry.
Invasiveness of RIE cell transfectants was assessed in Transwell inserts pre-coated with Matrigel (6.5 mm diameter, 8 μm pore size; BD Biosciences). DMEM containing 10% FBS was added to the lower chamber and 5×104 cells were suspended in serum-free DMEM (500 μl) and placed in the top chamber of the Transwell insert. Cells were incubated for 22 h at 37° C. in 5% CO2, at which time non-invading cells were removed from the upper chamber. Cells that had invaded through the Matrigel-coated filter were fixed in 100% methanol, stained with Crystal Violet and counted on a microscope using a calibrated ocular grid. Fifteen representative areas of the lower chamber were counted to determine the number of invasive cells in each well.
To assess anchorage-independent growth, RIE cell transfectants were suspended in DMEM supplemented with 10% FBS, 1.5% agarose, and a 1% insulin, transferrin and selenium solution (Sigma-Aldrich), and plated (300 cells/60 mm dish) on a layer of 1.5% agar containing the same medium. Cell colonies were fixed with 20% methanol and stained with Giemsa after 7-14 days in culture and quantified under a dissecting microscope.
Example 2 PKCι ExpressionThe potential involvement of PKCι in colon carcinogenesis was assessed by determining expression of PKCι in normal mouse colonic epithelium and in colon tumors induced by the carcinogen, azoxymethane (AOM). Immunoblot analysis demonstrated that PKCι expression is elevated in AOM-induced colon tumors when compared to matched, uninvolved colonic epithelium (
Immunohistochemical staining confirmed the elevated expression of PKCι in AOM-induced colon tumors in mice when compared to normal adjacent colonic epithelium (
The elevated expression of PKCι in colon tumors indicated that PKCι may play an important role in colon carcinogenesis. To test this hypothesis, transgenic mice were generated to express either a constitutively active (caPKCι) or kinase-deficient (kdPKCι) form of human PKCι in the colonic epithelium using a modified rat liver fatty acid binding protein promoter (Murray et al., J. Cell Biol., 157:915-920 (2002) and Simon et al., J. Biol. Chem., 272:10652-63 (1997)). Briefly, nucleic acid encoding caPKCι was generated by PCR-mediated site-directed mutagenesis and amplification of a fragment containing an alanine to glutamine (A120E) substitution within the pseudosubstrate domain of human PKCι (
Immunoblot analysis demonstrated that transgenic caPKCι and kdPKCι mice express elevated PKCι protein in the colonic epithelium (
To assess the importance of PKCι in colon carcinogenesis, transgenic caPKCι, transgenic kdPKCι, and non-transgenic mice were treated with AOM (Gokmen-Polar et al., Cancer Res., 61:1375-81 (2001) and Murray et al., J. Cell Biol., 145:699-711 (1999)). Initially, mice were analyzed 12 weeks after AOM treatment for the development of preneoplastic colonic lesions, aberrant crypt foci (ACF) (
The effect of transgenic caPKCι expression on colon tumor formation was assessed. Transgenic caPKCι mice exhibited a three-fold higher incidence of tumors than non-transgenic control mice [63.6% (7/11) versus 20% (2/10) tumor-bearing mice]. In addition to an increase in tumor incidence, transgenic caPKCι mice developed predominantly malignant intramucosal carcinomas (6/7 tumors;
A relationship may exist between PKCι and Ras signaling (Coghlan et al., Mol. Cell. Biol., 20:2880-9 (2000); Kampfer et al, J. Biol. Chem., 276:42834-42 (2001); and Uberall et al., J. Cell Biol., 144:413-25 (1999)). The importance of PKCι in Ras-mediated transformation of the intestinal epithelium was assessed. Rat intestinal epithelial (RIE) cells were used to study Ras-mediated transformation and to elucidate the molecular mechanisms by which PKCβII promotes a pro-carcinogenic phenotype (Murray et al., J. Cell Biol., 157:915-920 (2002); Sheng et al., J. Biol. Chem., 275:6628-35 (2000); and Yu et al, J. Biol. Chem., 278:11167-74 (2003)). RIE cells stably transfected with oncogenic V12H-ras (RIE/Ras) were transfected with FLAG-tagged-, wild-type (wt) PKCι, or kdPKCι. Both RIE/Ras/wtPKCι and RIE/Ras/kdPKCι cells expressed elevated levels of PKCι when compared to RIE or RIE/Ras cells (
Immunoprecipitation kinase assays (Jamieson et al., J. Biol. Chem., 274:3927-3930 (1999)) were performed on RIE, RIE/Ras, RIE/Ras/wtPKCι, and RIE/Ras/kdPKCι cells to assess total PKCι activity in these cell lines (
RIE/Ras cells exhibit an increase in anchorage-dependent growth rate and saturation density when compared to RIE cells (
Ras transformation is dependent upon Ras-mediated activation of the small molecular weight GTPase, Rac1 (Qiu et al., Nature, 374:457-9 (1995)). Therefore, Rac1 activity in RIE/Ras cells was measured (
Both Ras and Rac1 have been implicated in cellular motility and invasion (De Corte et al., Embo. J., 21:6781-90 (2002)) and RIE/Ras cells exhibit an invasive phenotype (Fujimoto et al., Exp. Cell Res., 266:239-49 (2001)). The following was used to assess whether the invasive phenotype observed in RIE/Ras cells is dependent upon Rac1 and PKCι. RIE/Ras cells exhibited a highly invasive phenotype in Matrigel chambers, whereas RIE cells did not (
RIE/Ras cells exhibited anchorage-independent growth in soft agar, whereas RIE cells did not (
The importance of PKCι in Ras-mediated colon carcinogenesis in vivo was assessed. For this purpose, a mouse model of Ras transformation consisting of a latent oncogenic K-ras allele (G12D) that is activated by spontaneous recombination in vivo was used (Johnson et al., Nature, 410:1111-6 (2001)). Latent K-ras (K-RasLA2) mice develop Ras-dependent lung carcinomas and ACF in the colonic epithelium (Johnson et al., Nature, 410:1111-6 (2001)). The transgenic kdPKCι mice were bred with K-RasLA2 mice to generate bitransgenic K-RasLA2/kdPKCι mice, which were then assessed for spontaneous ACF development (
Taken together, these results provide direct evidence that PKCι and Rac1 are necessary for the transformed phenotype induced by oncogenic Ras. Rac has previously been shown to be required for transformation by both H-Ras and K-Ras, the two most commonly mutated forms of Ras in human cancers. The data provided herein demonstrate that like, Rac1, PKCι is also required for both H-Ras and K-Ras-mediated transformation. Whereas H-Ras and K-Ras have been shown to have both common and distinct effectors, recent evidence indicates that both of these Ras isoforms activate Rac 1, though K-Ras appears to be able to activate Rac1 more effectively than does H-Ras (Walsh et al., J. Biol. Chem., 276:15609-15 (2001)). The data provided herein also demonstrate that H-Ras induces Rac1 activity through a PKCι-dependent pathway and that PKCι is required for K-Ras mediated colon carcinogenesis. Given the increased propensity of K-Ras to activate Rac 1, it is therefore quite likely that the Ras, PKCι, Rac 1 pathway present in RIE cells is also involved in K-Ras-mediated colon carcinogenesis in vivo. Interestingly, PKCι and Rac1 have also been implicated in the establishment of epithelial cell polarity through the formation of complexes containing PKCι, the Par6 polarity protein and Rac1 (Noda et al., Genes Cells, 6:107-19 (2001)). Rac1 is thought to regulate PKCι activity within these complexes to affect cell polarity (Noda et al., Genes Cells, 6:107-19 (2001)). The data further implicate signaling through PKCι/Par6/Rac1 complexes in Ras-mediated transformation.
These results provide conclusive evidence that PKCι activity is critical for colonic epithelial cell transformation in vivo. However, disruption of PKCι signaling (by expression of kdPKCι) has little effect on normal intestinal epithelial cell homeostasis in vitro and in vivo. Taken together, these characteristics indicate that PKCι can be an attractive target for development of novel therapeutics against colon cancer.
Example 5 PKCι Expression Levels in Human CancersImmunoblot analysis and/or immunohistochemistry was used to examine the expression of PKCι polypeptides in samples of human cancers and human cancer cell lines. Elevated expression of PKCι polypeptides was detected in the following cancers: colon, lung, head and neck, ovary, esophagus, prostate, ovary, kidney, and pancreas. More than 80 patient cases of adenocarcinoma and squamous carcinoma of the lung for PKCι expression were analyzed by both immunoblot analysis and immunohistochemistry using tissue arrays. Representative results are shown in
Non-small cell lung cancer (NSCLC) is the most common cause of cancer death in the United States. Long-term survival in NSCLC is low, indicating a need for better prognostic and therapeutic tools to detect and treat this disease. PKCι is highly expressed in human non-small cell lung cancer cell lines and primary tumors, and is required for transformed growth of lung cancer cells in vitro and tumorigenicity in vivo. PKCι activates a Rac1→Pak1→Mek1,2→Erk1,2 signaling pathway that regulates lung cancer growth. In addition, the PKCι gene is frequently amplified in lung squamous cell carcinoma cell lines and primary tumors, and PKCι expression predicts poor survival in patients with lung adenocarcinoma.
Methods and MaterialsExperimental Procedures Reagents: Antibodies were from the following sources and were used at the indicated concentrations: anti-PKCζ (Santa Cruz #sc-17640; 1:100), PKCι (Transduction Labs #P20520; 1:4000), actin (Santa Cruz #sc-1616; 1:2000), the FLAG epitope (Sigma # A8592; 1:2000), Rac1 (Transduction Labs #610651; 1:3000), cIAP2 (Santa Cruz #sc-7944; 1:500), Bcl-XL (Cell Signaling #2762; 1:1000), PARP/cleaved PARP (Cell Signaling #9542; 1:1000), MEK, Phospho-(Ser217/221)-MEK and Phospho-(Ser298)-MEK (Cell Signaling #9122,9121 and 9128; 1:1000), ERK and Phospho-(Thr202/Tyr204)-ERK (Cell Signaling #9102/9101; 1:1000), CD31 (or Pecam-1; Santa Cruz #sc-1506; 1:1000), and BrdU (DAKO # M0744; 1:100). TUNEL staining was performed using the TdT-FragEL DNA fragmentation detection kit (Calbiochem #QIA33). Recombinant human PKCι and PKCζ polypeptides were obtained from Upstate Biochemical (#14-505 and #14-525, respectively). The myristoylated atypical PKC pseudosubstrate inhibitor peptide was obtained from Biosource (#77-749).
Cell Culture, Plasmids, Transfections and Drug Treatments: Human A549, ChaGo-K-1, H292, H520, H1299, and SK-MES-1 non-small cell lung cancer cell lines as well as the non-transformed HBE4 lung epithelial cell line were obtained from ATCC (Manassas, Va., USA) and maintained as suggested by the supplier. The cells were maintained in a humidified tissue culture incubator at 37° C. in 5% CO2. A549, H1299, and ChaGo-K-1 cells were stably transfected with recombinant pBabe retroviruses containing Flag-tagged human full-length wild-type PKCι (wtPKCι), kinase dead PKCι (kdPKCι), or empty vector as described previously (Lu et al., Oncogene, 20:4777-4792 (2001)). Expression of FLAGepitope-tagged PKCι and total PKCι was analyzed by immunoblot analysis as described previously (Murray et al., J. Cell Biol., 164:797-802 (2004)).
Adherent growth kinetics of A549 and H1299 cells transfected with empty pBabe, pbabe/kdPKCι, or pbabe/wtPKCι were determined by plating cells (1×104 cells/well) into multi-well culture dishes and monitoring cell growth daily over a seven day period. Each day, cells from triplicate wells were trypsinized and counted using a hemocytometer. In some experiments, A549 cells were maintained in medium containing either 10%, 2%, or no fetal bovine serum.
Cell Invasion and Soft Agar Growth Assays: A549 and H1299 transfectants were assayed for cell invasion using Matrigel-coated Transwell cell culture chambers (6.5-mm diameter, 8-μm pore size; BD Biosciences). A549 and H1299 cell transfectants in logarithmic growth phase were harvested with trypsin, the trypsin neutralized with serum-containing medium, and the cells pelleted and resuspended in serum-free growth medium. 2.5×104 cells were placed into the upper chamber of the Transwell insert, and growth medium containing 10% FBS was added to the lower chamber. After 22 hours at 37° C. in 5% CO2, non-invasive cells in the upper chambers were removed and invasive cells were fixed in 100% methanol and stained with 0.5% crystal violet (Sigma) in 2% ethanol. Cells which had invaded through the Matrigel-coated filter were counted on a microscope (X40, Olympus) using a calibrated ocular grid.
Anchorage-independent growth was assayed by the ability of cells to form colonies in soft agar. The bottom agar consisted of growth medium containing 10% FBS and 0.75% agarose in 60-mm tissue culture dishes. Nine hundred cells were resuspended in growth medium containing 10% FBS and 0.75% agarose, and plated on top of the bottom agar. The cells were incubated at 37° C. in 5% CO2. Cell colonies were visualized and quantified under a dissecting microscope (Olympus) after 4-6 weeks in culture.
Rac 1 Activity Assays: Rac1 activity in A549 and H1299 cell transfectants was assessed by affinity isolation of GTP-bound Rac1 using binding domains of PAK as described previously (Sander et al., J. Cell Biol., 143(5):1385-98 (1998)). Briefly, cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM MgCl2, 5 mM EGTA, 10% glycerol, 1% Triton X-100, 1% NP-40, 25 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 10 μg/ml leupeptin, 10 μg/ml aprotinin) at 4° C. for 5 min. Cellular debris was removed by centrifugation at 20,000×g for 5 min, and supernatants were transferred to new tubes containing 20 μl of GST-p21-binding domain of PAK1 (PAK1-PBD) coupled to agarose beads (Upstate). An aliquot of each supernatant was reserved to determine total Rac1 and actin expression by immunoblot analysis. Following a 30-minute incubation at 4° C., the agarose beads were collected by centrifugation and washed three times in wash buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM MgCl2, 5 mM EGTA, 10% glycerol, 1% Triton X-100, 1% NP-40, 25 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 10 μg/ml leupeptin, 10 μg/ml aprotinin). Bound polypeptides were solubilized by the addition of 30 μl of SDS sample buffer, resolved by SDS-PAGE, and subjected to immunoblot analysis for Rac1. An equivalent aliquot of the total cell lysate was subjected to immunoblot analysis to determine total Rac1 expression.
NF-κB Transcriptional Activity Assays: NF-κB transcriptional activity was assayed using a dual-luciferase reporter system (Promega) as described previously (Lu et al., Oncogene, 20:4777-4792 (2001)). In brief, A549 cells stably expressing kdPKCι or pBabe vector control were transiently transfected with 500 ng of 3×MHCLuc, a plasmid containing three NF-κB response elements from the MHC promoter linked to a luciferase reporter gene, and 25 ng of phRL-SV40 using the FuGene6 lipofection reagent (Roche Applied Science) as described by the manufacturer. Twenty four hours after transfection, NF-κB activity was stimulated with 50 ng/ml TNFα (R&D Systems) for 2 hours. Total cell extracts were prepared for the dual-luciferase assay according to manufacturer's (Promega) instructions. Firefly and Renilla luciferase activity were measured using a Veritas Microplate Luminometer (Turner BioSystems). The activity of Renilla luciferase was used as an internal control for transfection efficiency.
Tumorigenicity in Nude Mice: The growth of stably infected A549 human lung carcinoma cells as established subcutaneous tumors was studied in athymic nude mice (Harlan-Sprague-Dawley, Indianapolis, Ind.) in a defined pathogen-free environment. Briefly, A549 cell transfectants were grown in F-12K Nutrient Mixture containing 10% FBS. A549 cell transfectants were harvested and resuspended in serum-containing medium. 4-6 week old female nude mice were injected subcutaneously into the flank with 5×106 cells in 100 μl of growth medium. Once palpable tumors were established, tumor size was measured once a week. Tumor growth was quantified by measuring the tumors in three dimensions with calipers. Tumor volume (mm3) was calculated using the formula: 0.5236 (L×W×H), where L represents the length of the tumor, W represents the width of the tumor, and H represents the height of the tumor. Animals were individually monitored throughout the experiment. At the conclusion of the study, mice were injected intraperitoneally with 100 μg/g of 5-bromo-2-deoxyuridine (BrdU) 1 hour prior to sacrificing the mice by CO2 asphyxiation. Tumors were excised and divided into sections for protein extraction and tumor fixation. Total tumor extracts were prepared in SDS buffer [2% (w/v) SDS, 4 M urea, 62.5 mM Tris-HCl (pH 6.8), 1 mM EDTA, 5% (v/v) β-mercaptoethanol] and equal amounts of polypeptide were subjected to immunoblot analysis as described herein. A section of tumor was also fixed in 10% buffered formalin, embedded in paraffin, sectioned (5 μm thickness), and stained for appropriate antigens.
Immunoblot Analysis Cells were harvested by washing with PBS and scraping off the plate. The cell pellet was lysed in SDS sample buffer. Protein lysates were quantitated by using the nitration of tyrosine in nitric acid (Bible et al., Anal. Biochem., 267(1):217-21 (1999)). Equal amounts of protein (˜20 μg) were loaded for each sample, resolved in 12% or 4-20% SDS-PAGE gels (Invitrogen) and transferred to PVDF membrane (Millipore Immobilin-P). A solution of 5% milk and PBS-Tween 20 was used for blocking TBS-Tween 20 was used for phospho-specific antibodies. Western blot analysis was performed with appropriate antibodies and detected using ECL-Plus (Amersham).
Analysis of Human Lung Cancer Tissues: H&E stained sections of matched normal and lung tumor tissues were analyzed by a pathologist in order to confirm initial diagnosis, staging, and overall integrity of the tissue samples. Based on this analysis, 40 cases of squamous cell carcinoma of the lung, 40 cases of adenocarcinoma of the lung, and matched normal lung tissues were chosen for extraction of DNA, RNA, and protein. Ten 10 μm thick slices were cut from each frozen block. DNA was isolated in phenol/chloroform, total RNA was isolated using RNAqueous 4PCR kit (Ambion), and protein was isolated by direct solubilization in SDS-PAGE sample buffer.
Real Time PCR Analysis for PKCι Gene Amplification: Genomic DNA from each sample was analyzed for amplification of PKCι using TaqMan technology on an Applied Biosystems 7900HT sequence detection system. The human RNaseP1 gene was used as a DNA template control and for normalization of results to total DNA. The primer/probe set for the human PKCι gene was as follows: forward primer, 5′-GGC-TGCATTCTTGCTTTCAGA-3′ (SEQ ID NO:9); reverse primer, 5′-CCAAAAATA-TGAAGCCCAGTAATCA-3′ (SEQ ID NO:10); and probe: 5′-CAATCTTACCTG-CTTTCT-3′ (SEQ ID NO:11). The primer/probe set for the RNAseP1 gene was designed and provided by ABI Assay on Demand.
Real-time Reverse Transcriptase-PCR Analysis of PKCι mRNA Abundance: PKCι mRNA abundance was determined by real-time Reverse Transcriptase-PCR using TaqMan technology on Applied Biosystems 7900HT sequence detection system. Human glyceraldehyde-3-phosphate dehydrogenase was used as an endogenous control. Samples were subjected to RT-PCR in the absence of reverse transcriptase controlled for the presence of genomic DNA. The primer/probe set for human PKCι mRNA spans the exon 16/17 border and was as follows: forward primer, 5′-CGTTCTTCCGAAATGTTGAT-TG-3′ (SEQ ID NO:12); reverse primer, 5′-TCCCCAGAAATATTTGGTTTAAAGG-3′ (SEQ ID NO:13); and probe, 5′-TTGCTCCATCATATCC-3′ (SEQ ID NO:14).
Analysis of PKCι Polypeptide Expression: Polypeptides from human tumor samples was quantified using nitric acid mediated nitration of tyrosine (Bible et al., Anal. Biochem., 267(1):217-21 (1999)). Equal amounts of polypeptide (˜30 μg) from each sample was resolved in 12% SDS-PAGE gels (Invitrogen), transferred to PVDF membrane (Millipore Immobilin-P), and subjected to immunoblot analysis using the appropriate antibodies and ECL-Plus detection (Amersham) as described previously (Murray et al., J. Cell Biol., 164:797-802 (2004) and Zhang et al., J. Biol. Chem., 279, 22118-22123 (2004)). Images were obtained on X-omat AR film, and antigens quantified by fluorescence detection using a Typhoon 9410 Variable Mode Imager. The fluorescent signal was analyzed using ImageQuant 5.2 software (Amersham).
Immunohistochemistry was performed on paraffin embedded sections of primary tumor and normal lung tissues. The tissue was deparaffinized by placing slides into 3 changes of xylene and rehydrated in a graded ethanol series. The rehydrated tissue samples were rinsed in water and subjected to antigen retrieval in citrate buffer pH 6.0 as described by the manufacturer (Dako). Slides were treated with 3% H2O2 for five minutes to reduce endogenous peroxidase activity and washed with PBS containing 0.5% (w/v) Tween 20. PKCι was detected using PKCι antibody at a 1:100 dilution in PBS/Tween and visualized using the Envision Plus Dual Labeled Polymer Kit following the manufacturer's instructions (Dako). Images were captured and analyzed using ImagePro software.
Statistical and Survival Analysis: Cancer-specific survival was estimated using the Kaplan-Meier method. The duration of follow-up was calculated from the sample date to the date of death or last follow-up. The associations of the clinical and pathologic features studied with death from lung cancer were assessed using Cox proportional hazards regression models and summarized with risk ratios and 95% confidence intervals (CI). Natural logarithmic transformations were explored if the distributions of continuously scaled variables were not approximately normal. In addition, the relationships between continuously scaled variables and death from lung cancer were investigated using martingale residuals from the Cox model (Therneau et al., Modeling Survival Data: Extending the Cox Model. First edition Ann Arbor, Springer-Verlag, (2000)). Statistical analyses were performed using the SAS software package (SAS Institute; Cary, N.C.) and p-values <0.05 were considered statistically significant.
ResultsAtypical PKCι Expression is Elevated in Human NSCLC Cells: The expression of PKCι and PKCζ in established human NSCLC cell lines was assessed. Immunoblot analysis of total cell lysates from six human NSCLC cell lines (A549, H1299, H292, ChaGoK1, Sk-Mes1, and H520) revealed that each cell line expressed elevated levels of PKCι when compared to non-transformed human HBE4 lung epithelial cells (
PKCι is Required for Human NSCLC Cell Transformation in vitro: Having identified PKCι as the major atypical PKC isozyme expressed in human NSCLC cell lines, the role of PKCι in the transformed phenotype exhibited by lung cancer cells was examined. A549 cells, a commonly studied LAC cell line, were stably transfected with retroviruses expressing either wild type human PKCι (wtPKCι), a kinase deficient PKCι mutant (kdPKCι) which acts in a dominant negative fashion (Jamieson et al., J. Biol. Chem., 274, 3927-3930 (1999) and Murray et al., J. Cell Biol., 164:797-802 (2004)), or empty retroviral vector (pBabe). Immunoblot analysis using an anti-Flag antibody confirmed expression of the appropriate recombinant PKCι polypeptides and a PKCι-specific antibody monitored total PKCι polypeptide expression (
Despite having no effect on adherent growth or survival of A549 cells, expression of kdPKCι had a dramatic inhibitory effect on several aspects of the transformed phenotype of A549 cells. Thus, A549/pBabe and A549/wtPKCι cells exhibited a highly invasive phenotype as measured by invasion through Matrigel-coated chambers, whereas A549/kdPKCι cells showed a significantly reduced invasive potential (
To assess whether the effects of kdPKCι on transformation were specific to A549 cells, H1299 cells, a SCC cell line, stably expressing either wtPKCι or kdPKCι were established (
Rac1 is a Downstream Target of PKCι in Lung Cancer Cell Transformation: The relative importance of Rac1 and NF-κB in mediating PKCι-dependent transformation of NSCLC cells was assessed (
The involvement of NF-κB signaling in PKCι-dependent transformation was also assessed. NF-κB plays a role in the protection of NSCLC cells from apoptosis through direct transcriptional induction of expression of the antiapoptotic genes cIAP2 and Bcl-XL (Cheng et al., Oncogene, 19, 4936-4940 (2000); Jiang et al., Oncogene, 20, 2254-2263 (2001); and Webster et al., Endocrinology, 143, 3866-3874 (2002)). Neither wtPKCι nor kdPKCι had an effect on the steady-state levels of cIAP2 or Bcl-XL in either A549 or H1299 cells (
These results are interesting in light of the results obtained in other cell systems. For instance, in CML cells, PKCι is required for Bcr-Abl-mediated transformation and NF-κB was identified as a requisite downstream effector of PKCι-dependent cell survival (Jamieson et al., J. Biol. Chem., 274, 3927-3930 (1999); Lu et al., Oncogene, 20:4777-4792 (2001); and Murray et al., J. Biol. Chem., 272, 27521-27524 (1997)). In contrast, in rat intestinal epithelial (RIE) cells, the small molecular weight GTPase Rac1 was identified as a downstream effector of oncogenic Ras-mediated, PKCι-dependent transformation (Murray et al., J. Cell Biol., 164:797-802 (2004)). Thus, it appears that PKCι can contribute to transformation through activation of at least two different signaling pathways depending upon the cellular context.
The PB1 Domain is Involved in PKCι-dependent Transformation: The ability of kdPKCι to block Rac1 activity suggests that the kinase activity of PKCι is required for Rac1 activation in NSCLC cells. Treatment of A549 cells with the highly selective cell permeant atypical PKC pseudosubstrate peptide inhibitor, PSI, also blocks Rac1 activity (
The PKCι-Rac1 Signaling Axis is Required for Lung Cancer Cell Tumorigenicity in vivo: Since Rac1 was identified as a molecular target for PKCι in NSCLC cells, Rac1 was assessed for the ability to be a downstream effector of PKCι-dependent transformation. Expression of a constitutively active mutant of Rac1, RacV12, restores transformed growth of A549/kdPKCι cells in soft agar (
The status of Rac1 and NF-κB signaling in tumors derived from A549 cell transfectants was also assessed. Rac1 activity in A549 cell tumors was measured by monitoring the level of activity of the downstream Rac1 effector MEK 1/2. MEK 1/2 was demonstrated to be a PKCι- and Rac1-dependent molecular target in Ras-transformed RIE cells (Murray et al., J. Cell Biol., 164:797-802 (2004)). Immunoblot analysis of lysates from A549/pBabe cell tumors revealed significant levels of activated MEK that is phosphorylated on the Ser217/221 Raf activation sites on MEK1/2 (
Though no evidence for PKCι-dependent NF-κB activation in A549 cells was detected in vitro, it was possible that PKCι may be involved in maintenance of NF-κB activity and tumor survival in the in vivo setting. However, immunoblot analysis demonstrated that expression of the NF-κB transcriptional targets cIAP2 and Bcl-Xl were not affected by expression of kdPKCι or RacV12 (
PKCι is Critical for Tumor Cell Proliferation in vivo: The mechanism by which kdPKCι inhibits A549 tumor formation in vivo was assessed. As described herein, induction of apoptosis in A549 cells expressing kdPKCι was not observed, indicating that kdPKCι does not inhibit tumor formation by impairing tumor cell survival. However, BrdU labeling of A549 cell tumors revealed that A549/kdPKCι tumors exhibited a significant decrease in BrdU-positive, cycling tumor cells when compared to A549/pBabe tumors (
It is possible that A549/kdPKCι tumors exhibit a reduced proliferative index due to a reduction in tumor vascularization as a result of decreased angiogenesis. However, immunohistochemical staining with the endothelial cell marker CD31 revealed no change in tumor-associated vessel density in A549 cell tumors in the presence of kdPKCι or RacV12 (
PKCι Expression is Elevated in Primary Squamous Cell Carcinomas: The results provided herein demonstrate that PKCι expression is elevated in NSCLC cells, and that PKCι plays a role in NSCLC cell transformation in vitro and in vivo. In order to determine whether PKCι expression is relevant to human disease, atypical PKC expression in the two major sub-types of NSCLC, SCC and LAC, were assessed. Forty cases of SCC and matched normal lung tissues were initially selected for analysis. Three cases had received therapy prior to obtaining the tissue samples and were excluded from the analysis in order to eliminate the possible effect of treatment on PKCι expression. A fourth case was excluded because sufficient protein could not be obtained from both the normal and tumor tissues. The remaining 36 cases were analyzed by immunoblot analysis for expression of PKCι, PKCζ, and actin. Results from five representative cases are shown in
Quantitative analysis of the immunoblot data demonstrated a statistically significant increase in PKCι expression in SCC compared to normal lung tissue (
Whether PKCι polypeptide expression correlates with PKCι mRNA abundance was assessed in SCC tumors. Total RNA was isolated from 21 SCCs and matched normal samples and assessed for PKCι mRNA abundance by quantitative real time PCR. Spearman rank order analysis demonstrated a positive correlation between PKCι mRNA abundance and PKCι polypeptide expression in SCC (
PKCι Gene Amplification Regulates PKCι Expression in SCC Cell Lines and Primary SCC Tumors: Among the cytogenetic changes commonly found in lung SCCs, amplification of chromosome 3q26 is among the most frequent, occurring in about 40-50 percent of SCCs (Balsara et al., Cancer Res., 57, 2116-2120 (1997) and Brass et al., Cancer Res., 57, 2290-2294 (1997)). Multiple candidate oncogenes reside in the chromosome 3q26 region including the Ski-like gene SnoN (Imoto et al., Biochem. Biophys. Res. Commun., 286, 559-565 (2001)), the catalytic subunit of phosphatidylinositol-3 kinase (PI3Kα) (Singh et al., Genes Dev., 16, 984-993 (2002)), the Evil oncogene (Imoto et al., Biochem. Biophys. Res. Commun., 286, 559-565 (2001)), and the RNA component of human telomerase (TERC) (Yokoi et al., Clin. Cancer Res., 9, 4705-4713 (2003)). However, the importance of these genes in SCC formation has not been systematically evaluated. Since the human PKCι gene resides at 3q26, whether PKCι gene amplification occurs in SCC cell lines and primary tumors was assessed. Quantitative real time PCR analysis revealed PKCι gene amplification in 3 of the 4 established human SCC cell lines tested. Specifically, amplification was detected in H520, H1299, and ChaGo cells, but not in Sk-Mes1 or nontransformed HBE4 lung epithelial cells (
Whether PKCι gene amplification occurs in primary SCC tumors was assessed. Genomic DNA isolated from 36 SCC cases was analyzed for PKCι gene copy number by quantitative real time PCR. Amplification was quantitated by normalizing PKCι gene copy number to the single copy RNAse P gene and standardized to patient-matched normal lung tissue. PKCι gene amplification was observed in 17/36 (47.2%) of the cases. Statistical analysis demonstrated a significant increase in PKCι gene copy number in SCC compared to matched normal lung tissue (
PKCι Expression is Elevated in Lung Adenocarcinomas: Whether PKCι expression is elevated in LAC, the most prevalent form of NSCLC, was assessed. Forty primary LAC and matched normal lung tissue samples were initially selected for analysis. Four cases received therapy prior to sample collection and were excluded from the analysis. Immunoblot analysis from five representative cases is shown in
The vast majority (33/36 or 91.7%) of LACs exhibited elevated PKCι expression, and Spearman rank order statistical analysis demonstrated a significant increase in PKCι polypeptide expression in LAC compared with matched normal lung tissue (
PKCι Expression Predicts Poor Survival of Lung Adenocarcinoma Patients: The following was performed to determine whether PKCι polypeptide expression is of prognostic value for the assessment of patients with NSCLC. For this purpose, whether there is a correlation between PKCι expression and either disease stage or cancer-specific death in SCC and LAC was assessed. PKCι expression was determined on a continuous scale and normalized to matched normal lung tissue. In LAC, PKCι polypeptide expression correlated with an increased risk of cancer-specific death. Using Martingale residual analysis, the cases were divided into two groups based on PKCι expression. Patients in the high PKCι expression group were ten times more likely to die from LAC than patients in the low PKCι expression group (risk ratio 10.26, 95% CI 1.68-62.69; p=0.012) (
In SCC patients, a trend was observed between PKCι expression and cancer-specific death but the correlation did not reach statistical significance (p=0.21). The lack of a statistically significant correlation between PKCι expression and death in SCC may be due to molecular and genetic differences in these two forms of NSCLC. For instance amplification of the PKCι gene and other potential oncogenes present in the chromosome 3q26 amplicon in SCC may obscure a correlation between PKCι expression and clinical outcome. Alternatively, the small sample size analyzed may not have sufficient power to reveal a correlation between these parameters. Indeed, the well-established correlation between tumor grade and death from SCC, while observed in this patient data set, did not reach statistical significance (risk ratio 3.10, p=0.057), indicating that the sample size did not provide sufficient power for the intended analysis. Additional analysis using a larger patient data set can be used to resolve between these possibilities. In conclusion, the results provided herein demonstrate that PKCι plays a role in lung cancer cell transformation. The results that PKCι is dispensable for adherent cell growth and survival indicate that PKCι signaling is an attractive target for the development of new therapeutics for the treatment of lung cancer.
Example 7 Identifying Compounds that Inhibit PKCι Binding, PKCι Activity, and TumorigenicityA primary screen was performed as follows to identify test compound having the potential to inhibit the interaction of PKCι polypeptides with PAR6 polypeptides. Bacterially expressed PKCι
To perform the assay, PYN was diluted to 4000 relative fluorescent units/50 μl in Tris buffer plus 1 M urea, and PAR6125-CFP-C1 was diluted to 400 relative fluorescent units/50 μl Tris buffer plus 1 M urea. To each well of a 96-well, clear-bottom black plate (Costar 3631), 50 μl of PYN and 50 μl of PAR6125-CFP-C1 were added, followed by 10 μl of undiluted test compound from the GenPlus library (final concentration of test compound=1 mM). Plates were incubated at 4° C. for about 3-4 hours. Fluorescence was measured in a SpectraMax Gemini plate reader. Cyan fluorescence was measured at excitation 395 nm, emission 475 nm, and cutoff of 455 nm. Yellow fluorescence was measured at excitation 395 nm, emission 529, and cutoff of 515 nm. To determine the degree of FRET occurring in the sample, the cyan fluorescence was divided by yellow fluorescence, and compared to samples with only vehicle (DMSO) present.
142 test compounds were identified as being hits with the primary screen (Table 2). These positive hits were from various classes of compounds including flavonoids, dopamine agonist, selenium-containing compounds, etc.
Multiple test compounds that were classified as hits in the primary screen as well as additional related compounds were evaluated in a secondary screen designed as follows. Briefly, a 96-well microtiter plate coated with streptavidin (Nunc #436014) was incubated for 2-4 hours at room temperature with 100 μl of a 20-30 μg/ml solution of biotin-tagged PAR6 (whole polypeptide) in phosphate-buffered saline containing Tween-20 (PBST). Plates were washed twice with PBST, then once with incubation buffer (50 mM Tris, pH 8.0; 135 mM NaCl; 10% glycerol; 0.002% EDTA). Incubation buffer (50 μl) was added to each well. The compounds to be tested were added (10 μl) followed by PYN (50 μl) diluted in incubation buffer to an approximate concentration of 4000-5000 relative fluorescent units per 50 μl. Plates were incubated overnight at 4° C. Plates were washed twice with incubation buffer, after which 50 μl incubation buffer was added to retain moisture in the wells. The amount of PYN bound on the plates was determined by measuring yellow fluorescence (532/526) in a Typhoon imager. Fluorescence was quantitated by Softmax Pro software.
The following test compounds were confirmed via the secondary screen as having the potential to inhibit the interaction of PKCι polypeptides with PAR6 polypeptides: aurothioglucose, thimerosal, phenylmercuric acetate, ebselen, cisplatin, apomorphine, pyrantel pamoate, gossypol-acetic acid complex, ellagic acid, and hexestrol. A dose-response analysis was performed using the secondary screening assay and increasing amounts (e.g., 0, 0.1, 1, 10, 100, and 100 μM) of gossypol, hexestrol, thimerosal, ebselen, ATG, ATM, ellagic acid, cisplatin, apomorphine, or phenylmercuric acetate. In each case, a dose-dependent response was detected as the dose increased.
A dose-response analysis was performed using aurothioglucose (ATG) and aurothiomaleate (ATM) in the FRET assay that was used as the primary screen. Both compounds exhibited a dose-dependent effect on relative binding of PKCι and PAR6 polypeptides with less binding being observed as the ATG or ATM concentrations increased (
Rac 1 Activity Assays: A549 cells were incubated with the indicated concentration of ATG for one hour prior to analysis. Rac1 activity in A549 cells was assessed by affinity isolation of GTP-bound Rac1 using binding domains of PAK as described elsewhere (Sander et al., J. Cell Biol., 143:1385-98 (1998)). Briefly, cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM MgCl2, 5 mM EGTA, 10% glycerol, 1% Triton X-100, 1% NP-40, 25 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 10 μg/ml leupeptin, and 10 μg/ml aprotinin) at 4° C. for 5 min. Cellular debris was removed by centrifugation at 20,000×g for 5 min, and supernatants were transferred to new tubes containing 20 μl of GST-p21-binding domain of PAK1 (PAK1-PBD) coupled to agarose beads (Upstate). An aliquot of each supernatant was reserved to determine total Rac1 and actin expression by immunoblot analysis. Following a 30 minute incubation at 4° C., the agarose beads were collected by centrifugation and washed three times in wash buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM MgCl2, 5 mM EGTA, 10% glycerol, 1% Triton X-100, 1% NP-40, 25 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 10 μg/ml leupeptin, and 10 μg/ml aprotinin). Bound polypeptides were solubilized by the addition of 30 μl of SDS sample buffer, resolved by SDS-PAGE, and subjected to immunoblot analysis for Rac1.
Treatment of cells with ATG resulted in decreased Rac1 activity (
Soft Agar Growth Assays: Anchorage-independent growth was assayed by the ability of cells to form colonies in soft agar. The bottom agar consisted of growth medium containing 10% FBS and 0.75% agarose in 60-mm tissue culture dishes. Nine hundred cells were resuspended in growth medium containing 10% FBS and 0.75% agarose and plated on top of the bottom agar. ATG was added at the indicated concentration to both bottom and top agar solutions. The cells were incubated at 37° C. in 5% CO2. Cell colonies were visualized and quantified under a dissecting microscope (Olympus) after 4-6 weeks in culture.
Treatments with 10 μM and 100 μM of ATG resulted in decreased soft agar growth (
Tumorigenicity in Nude Mice: The growth of A549 human lung carcinoma cells as established subcutaneous tumors was studied in athymic nude mice (Harlan-Sprague-Dawley, Indianapolis, Ind.) in a defined pathogen-free environment. Briefly, A549 cells were grown in F-12K Nutrient Mixture containing 10% FBS. A549 cells were harvested and resuspended in serum-containing medium. 5×106 cells in 100 μl of growth medium were injected subcutaneously into the flank of 4-6 week old female nude mice. Once palpable tumors were established (15 days after inoculation) animals were randomly segregated into two groups. One group received intraperitoneal injections of ATG (200 mg/kg body weight) daily; the second group received an equivalent volume of diluent control solution. Tumor size was measured daily. Tumor growth was quantified by measuring the tumors in three dimensions with calipers. Tumor volume (mm3) was calculated using the formula: 0.5236 (L×W×H), where L represents the length of the tumor, W represents the width of the tumor, and H represents the height of the tumor. Animals were individually monitored throughout the experiment.
Animals treated with ATG exhibited less tumor growth than the tumor growth exhibited in animals treated with saline (
A tetracycline-based bitransgenic, regulatable expression system has been used to create conditional expression of transgenes specifically in the lung epithelium. Transgenic mice expressing reverse tet transactivator (rtTA) from either the surfactant protein C(SP-C) or Clara Cell Specific Protein (CCSP) promoter allow conditional expression of tet-responsive gene constructs in the lung epithelium. When SP-C-rtTA (or CCSP-rtTA) mice are crossed to transgenic mice expressing a (tetO)7-CMV-transgene, expression of the transgene can be targeted to the lung epithelium under the control of doxycycline. This system has been used to establish the role of oncogenic K-Ras mutations in LAC development and maintenance (Fisher et al., Genes Dev., 15:3249-3262 (2001)). Crossing CCSP-rtTA mice to transgenic mice expressing (tetO)7-CMV-K-RasG12D, generated mice in which oncogenic K-Ras can be conditionally expressed in the lung epithelium by addition of doxycycline to the drinking water. CCSP-rtTA/(tetO)7-K-RasG12D bitransgenic mice develop multiple LACs only after administration of doxycycline. Interestingly, when doxycycline is withdrawn, tumors rapidly regress due to massive apoptosis, showing that K-RasG12D is necessary for both tumor establishment and maintenance.
Bitransgenic mice were developed to allow conditional expression of kdPKCι in the lung epithelium under the control of doxycycline. To construct this model, transgenic SP-C-rtTA “inducer” mice expressing the reverse tetracycline transactivator protein (rtTA) specifically in the lung epithelium under the control of the SP-C promoter were obtained. In addition, transgenic “responder” mice expressing kdPKCι under the control of a tet responsive promoter, tet(07)-CMV were generated. These mice exhibit germline transmission of a tet(07)-CMV-FLAG-kdPKCι transgene designed to support tet-regulated expression of FLAG-kdPKCι. Three independent transgenic tet(07)-CMV-FLAG-kdPKCι mouse lines were established. One of these lines was crossed to SP-C-rtTA mice to establish bitransgenic SPC-rtTA/tet-kdPKCι mice. When bitransgenic SPC-rtTA/tet-kdPKCι mice are given doxycycline in their drinking water, they exhibit tet-regulated expression of FLAG-kdPKCι mRNA in the lung epithelium as determined by QRT-PCR. The kdPKCι transgene was not detected in other tissues (liver, thymus, colon or kidney), indicating that conditional expression is specific to the lung.
Similar mice can be made to express wild-type PKCι polypeptides or caPKCι polypeptides instead of kdPKCι polypeptides.
Other EmbodimentsIt is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims
1. A method for inhibiting a protein kinase C iota polypeptide response in a mammal, said method comprising administering an inhibitor to said mammal under conditions wherein said response is inhibited, wherein said inhibitor reduces the interaction between a protein kinase C iota polypeptide and a polypeptide selected from the group consisting of Par-6, Src, Par-4, p62/ZIP, and Par-3 polypeptides.
2. The method of claim 1, wherein said response is cell transformation, development of cancer, or colon carcinogenesis.
3. The method of claim 1, wherein said inhibitor is a polypeptide fragment.
4. The method of claim 3, wherein said polypeptide fragment comprises an amino acid sequence present in said protein kinase C iota polypeptide.
5. The method of claim 1, wherein said inhibitor is aurothioglucose, aurothiomaleate, thimerosal, phenylmercuric acetate, ebselen, cisplatin, apomorphine, pyrantel pamoate, gossypol-acetic acid complex, ellagic acid, or hexestrol.
Type: Application
Filed: Oct 1, 2009
Publication Date: Apr 15, 2010
Inventors: Alan P. Fields (Jacksonville, FL), Nicole Renee Murray (Ponte Vedra Beach, FL), Melody Lee Stallings-Mann (Jacksonville, FL), Lee Jamieson (Jacksonville, FL)
Application Number: 12/571,620
International Classification: A61K 33/24 (20060101); A61K 31/395 (20060101); A61K 31/485 (20060101); A61K 31/305 (20060101); A61K 31/495 (20060101); A61K 31/185 (20060101); A61K 31/352 (20060101); A61P 35/00 (20060101);
